Revolutionising the Analysis of Hematologic Malignancies: Multiple Myeloma and Acute Lymphoblastic Leukemia
We are pleased to announce the launch of two new SALSA® digitalMLPA™ assays in the field of hematologic malignancies: D006 Multiple Myeloma and D007 Acute Lymphoblastic Leukemia.
These two novel digitalMLPA assays combine the confidence in CNV calling of our trusted MLPA technology, with the broad coverage of next generation sequencing.
SALSA® digitalMLPA Probemix D006 Multiple Myeloma targets all non-acrocentric chromosomal arms to enable the detection of large copy number alterations and ploidy changes. Chromosomal regions that are frequently altered in multiple myeloma, including 1q, 1p, 13q and 17p, are especially well covered, allowing for a high resolution screening of these arms. The assay also targets genes of emerging significance, such as BCMA and GPRC5D.
SALSA® digitalMLPA Probemix D007 Acute Lymphoblastic Leukemia targets 55 genes and regions including IKZF1, iAMP21, ERG and many more. In addition, the D007 Acute Lymphoblastic Leukemia assay also covers most chromosomal arms, allowing for the detection of gross copy number alterations and ploidy status.
If you would like more information about the digitalMLPA™ technology, please visit this page or sign up for our upcoming Webinar: Get to Know digitalMLPA (12 January).
For Research Use Only (RUO). Not for use in diagnostic procedures.